Table 5.
Risk assessment in patients with pulmonary arterial hypertension
| Criterion | Low risk* | Intermediate risk† | High risk‡ |
|---|---|---|---|
| Estimated 1-year mortality, % | <5 | 5–10 | >10 |
| WHO functional class | I, II | III | IV |
| 6-minute walking distance (m) | >440 | 165–440 | <165 |
| Biochemical test | |||
| BNP (ng/L) | <50 | 50–300 | >300 |
| NT-proBNP (pg/mL) | <300 | 300–1,400 | >1,400 |
| Hemodynamic profile | |||
| RA pressure (mmHg) | <8 | 8–14 | >14 |
| CI (L/min/m2) | ≥2.5 | 2.0–2.4 | <2.0 |
| SvO2 (%) | >65 | 60–65 | <60 |
Modified from Thomas CA et al. Pulm Ther 2020;6:9–22, according to the Creative Commons license [23].
*
At least three low risk criteria and no high-risk criterion.
†
Definitions of low or high risk are not fulfilled.
‡
At least two high-risk criteria, including CI or SvO2.
WHO: World Health Organization; BNP: B-type natriuretic peptide; NT-proBNP: N-terminal pro-B-type natriuretic peptide; RA: right atrial; CI: cardiac index; SvO2: mixed venous oxygen saturation.